Casadei Gardini Andrea, Tamburini Emiliano, Iñarrairaegui Mercedes, Frassineti Giovanni Luca, Sangro Bruno
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Department of Medical Oncology, Ospedale Infermi, Rimini, Italy.
Onco Targets Ther. 2018 Oct 25;11:7315-7321. doi: 10.2147/OTT.S175715. eCollection 2018.
This study aimed to compare clinically relevant outcomes following transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) in patients with unresectable hepatocellular carcinoma (HCC) using only prospective randomized clinical trials as a source of information.
A meta-analysis was performed to compare the efficacy of TARE and TACE in treating patients with unresectable HCC. Only prospective randomized trials were included in the quantitative analysis. Overall and progression-free survival, disease control rate, and transplantation rate were the variables under analysis.
Overall survival at 1 year was similar between the two treatment groups (OR =1.31, 95% CI: 0.56-3.04, =0.53). Progression-free survival at 1 year was also not statistically different between the two treatments (OR =0.23, 95% CI: 0.02-2.45, =0.22). Although a higher proportion of patients underwent transplantation in the TARE group (30% vs 20.8%), this difference was not statistically significant (OR =0.68, 95% CI: 0.23-2.01; =0.49).
TARE and TACE provide similar outcomes in unresectable HCC. The role of TARE should be explored in selected patient subpopulations in future clinical trials.
本研究旨在仅以前瞻性随机临床试验作为信息来源，比较经动脉化疗栓塞术（TACE）和经动脉放射性栓塞术（TARE）治疗不可切除肝细胞癌（HCC）患者后的临床相关结局。
进行一项荟萃分析，比较TARE和TACE治疗不可切除HCC患者的疗效。定量分析仅纳入前瞻性随机试验。总生存期和无进展生存期、疾病控制率及移植率为分析的变量。
两个治疗组1年总生存期相似（OR = 1.31，95%CI：0.56 - 3.04，P = 0.53）。两种治疗的1年无进展生存期在统计学上也无差异（OR = 0.23，95%CI：0.02 - 2.45，P = 0.22）。尽管TARE组接受移植的患者比例更高（30%对20.8%），但该差异无统计学意义（OR = 0.68，95%CI：0.23 - 2.01；P = 0.49）。
TARE和TACE在不可切除HCC患者中疗效相似。未来临床试验应在特定患者亚群中探索TARE的作用。
